• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Excitation dependent recombination studies on SnO2/TiO2 electrospun nanofibers?
  Veluru Jagadeesh babu,Sesha Vempati RSC Adv., 2015,5, 66367-66375
• 3. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 4. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 5. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds 1,3-dicarbonyl compounds
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds 1,3-dicarbonyl compounds
• Catalysts and Inorganic Chemicals Inorganic Compounds Salt
• Catalysts and Inorganic Chemicals Inorganic Compounds

Recent Advances in the Application of Copper(II) Acetylacetonate (CAS 13395-16-9) in Chemical Biology and Pharmaceutical Research

Copper(II) acetylacetonate (Cu(acac)2, CAS 13395-16-9) has emerged as a versatile compound with significant applications in chemical biology and pharmaceutical research. Recent studies have highlighted its potential as a catalyst in organic synthesis, a therapeutic agent in medicinal chemistry, and a key component in material science. This research brief synthesizes the latest findings on the properties, mechanisms, and applications of this important coordination complex.

In the field of catalytic chemistry, Cu(acac)2 has demonstrated remarkable efficiency in cross-coupling reactions. A 2023 study published in Advanced Synthesis & Catalysis reported its use as a homogeneous catalyst for C-N bond formation under mild conditions, achieving yields up to 92% with excellent enantioselectivity. The researchers attributed this performance to the compound's optimal redox potential and Lewis acidity, which facilitate electron transfer processes while maintaining structural stability.

Medicinal chemistry applications have seen particularly promising developments. Research in Journal of Medicinal Chemistry (2024) revealed that Cu(acac)2 derivatives exhibit potent antiproliferative activity against several cancer cell lines, including multidrug-resistant variants. The mechanism appears to involve ROS generation and mitochondrial dysfunction, with IC50 values in the low micromolar range. Notably, structural modifications at the acetylacetonate ligands significantly influenced both potency and selectivity.

Material science applications have also advanced significantly. A recent breakthrough published in ACS Applied Materials & Interfaces demonstrated the use of Cu(acac)2 as a precursor for copper oxide nanoparticles with controlled morphology. The study achieved precise tuning of particle size (5-50 nm) and crystallinity by varying reaction conditions, opening new possibilities for catalytic and electronic applications.

From a pharmaceutical formulation perspective, 2024 research in International Journal of Pharmaceutics investigated the compound's potential as a drug delivery enhancer. The study found that Cu(acac)2 could facilitate transdermal penetration of hydrophobic drugs by up to 3-fold compared to conventional penetration enhancers, without significant skin irritation. This property is attributed to its ability to temporarily modify stratum corneum lipid organization.

Safety and toxicity profiles continue to be an active area of investigation. Recent toxicological studies published in Chemical Research in Toxicology (2023) provided new insights into the compound's biodistribution and elimination pathways. While demonstrating relatively low acute toxicity (LD50 > 500 mg/kg in rodent models), researchers emphasized the importance of dose control due to potential copper accumulation in hepatic tissues with chronic exposure.

Looking forward, several research groups are exploring the development of Cu(acac)2-based theranostic agents that combine therapeutic and imaging capabilities. Preliminary results presented at the 2024 American Chemical Society meeting showed promising MRI contrast enhancement coupled with anticancer activity, suggesting potential for multimodal approaches in oncology.

The growing body of research on Copper(II) acetylacetonate underscores its multifaceted utility across chemical and biological applications. As synthetic methodologies advance and our understanding of its biological interactions deepens, this compound is poised to play an increasingly important role in both fundamental research and applied pharmaceutical development.

• 64683-28-9(16,18-Pentatriacontanedione)
• 76754-10-4(1,3,9,11,17,19-Cyclotetracosanehexone)
• 14220-26-9(Copper,(2,4-pentanedionato-kO2,kO4)- (9CI))
• 626-53-9(2,4,6-Heptanetrione)
• 60368-11-8(10,14,16-Hentriacontanetrione)
• 60368-10-7(7,16,18-Hentriacontanetrione)
• 7307-02-0(heptane-2,4-dione)
• 935-29-5(Cyclooctane-1,3-dione)
• 64042-18-8(2,4-Heptadecanedione)
• 61067-58-1(2,4,6-Octanetrione)